ZA931797B - Peptides and nucleic acid sequences related to the epstein barr virus - Google Patents
Peptides and nucleic acid sequences related to the epstein barr virusInfo
- Publication number
- ZA931797B ZA931797B ZA931797A ZA931797A ZA931797B ZA 931797 B ZA931797 B ZA 931797B ZA 931797 A ZA931797 A ZA 931797A ZA 931797 A ZA931797 A ZA 931797A ZA 931797 B ZA931797 B ZA 931797B
- Authority
- ZA
- South Africa
- Prior art keywords
- peptides
- nucleic acid
- ebv
- antibodies
- acid sequences
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—DNA viruses
- C07K16/085—Orthoherpesviridae (F), e.g. pseudorabies virus or Epstein-Barr virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—DNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G01N33/56994—Herpetoviridae, e.g. cytomegalovirus, Epstein-Barr virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Microbiology (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP92200721 | 1992-03-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA931797B true ZA931797B (en) | 1993-09-30 |
Family
ID=8210477
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA931797A ZA931797B (en) | 1992-03-13 | 1993-03-12 | Peptides and nucleic acid sequences related to the epstein barr virus |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US5424398A (fr) |
| EP (2) | EP1225226B1 (fr) |
| JP (3) | JP4135996B2 (fr) |
| KR (1) | KR100291247B1 (fr) |
| AT (2) | ATE222291T1 (fr) |
| AU (1) | AU666920B2 (fr) |
| CA (1) | CA2092680C (fr) |
| DE (2) | DE69332197T2 (fr) |
| DK (2) | DK0574048T3 (fr) |
| ES (2) | ES2184735T3 (fr) |
| FI (1) | FI114802B (fr) |
| PT (1) | PT574048E (fr) |
| ZA (1) | ZA931797B (fr) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE207120T1 (de) * | 1993-07-23 | 2001-11-15 | Hans Prof Dr Wolf | Dna-sequenzen des epstein-barr virus kodierend für ein diagnostisch relevantes virus-hüllprotein,durch pcr erhaltene expressionsklone und verwendung dieses rekombinanten antigens in diagnostischen tests |
| ATE231556T1 (de) * | 1993-09-14 | 2003-02-15 | Biomerieux Bv | Diagnostische reagenzien zum nachweis von antikörper gegen ebv |
| US5834747A (en) | 1994-11-04 | 1998-11-10 | Pixel Instruments | Universal credit card apparatus and method |
| DE19526384C2 (de) * | 1995-07-19 | 1997-07-10 | Biotest Ag | Rekombinante autologe Fusionsproteine des Epstein-Barr-Virus, sowie diese enthaltende Testkits zum Nachweis von Epstein-Barr-Virus-spezifischen Antikörpern |
| US5813500A (en) * | 1996-03-25 | 1998-09-29 | Tenneco Automotive Inc. | Anti-swish mechanism for a damper |
| FR2765688B1 (fr) | 1997-07-04 | 1999-09-10 | Pasteur Institut | Reactif de detection et de suivi des infections provoquees par le virus d'epstein-barr et ses applications |
| US7105496B2 (en) * | 1998-07-23 | 2006-09-12 | Northwestern University | Methods and compositions for inhibiting angiogenesis |
| US6797691B1 (en) | 1997-07-23 | 2004-09-28 | Northwestern University | Methods and compositions for inhibiting angiogenesis |
| EP1627886A1 (fr) * | 1997-10-07 | 2006-02-22 | Ono Pharmaceutical Co., Ltd. | Polypeptides, ADNc le codant et leur utilisation |
| JP4472171B2 (ja) | 1998-03-04 | 2010-06-02 | アクゾ・ノベル・エヌ・ベー | エプスタイン−バーウイルス(ebv)核酸の増幅と検出のためのオリゴヌクレオチド |
| US20030064917A1 (en) * | 1998-07-23 | 2003-04-03 | Crawford Susan E. | Methods and compositions for inhibiting angiogenesis |
| US6159950A (en) * | 1998-10-16 | 2000-12-12 | Cornell Research Foundation, Inc. | Method of modulating hair growth |
| AU3988401A (en) * | 2000-02-25 | 2001-09-03 | Ludwig Inst Cancer Res | Materials and methods involving hybrid vascular endothelial growth factor dnas and proteins |
| US20030143647A1 (en) * | 2001-09-24 | 2003-07-31 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Anticancer vaccine and diagnostic methods and reagents |
| US7521053B2 (en) | 2001-10-11 | 2009-04-21 | Amgen Inc. | Angiopoietin-2 specific binding agents |
| US7138370B2 (en) | 2001-10-11 | 2006-11-21 | Amgen Inc. | Specific binding agents of human angiopoietin-2 |
| CA2481304A1 (fr) * | 2002-03-27 | 2003-10-09 | Patrick Hwu | Methode de traitement du cancer chez les humains |
| US7507568B2 (en) * | 2002-09-25 | 2009-03-24 | The Proctor & Gamble Company | Three dimensional coordinates of HPTPbeta |
| US7226755B1 (en) * | 2002-09-25 | 2007-06-05 | The Procter & Gamble Company | HPTPbeta as a target in treatment of angiogenesis mediated disorders |
| US6886670B2 (en) * | 2003-09-29 | 2005-05-03 | Tenneco Automotive Operating Company Inc. | Extra support land for valve disc |
| DE10307517A1 (de) * | 2003-02-21 | 2004-09-02 | Mikrogen Molekularbiologische Entwicklungs-Gmbh | Von Kapsidantigenen des Epstein-Barr-Virus abgeleitete Peptide und ihre Verwendung |
| US6899207B2 (en) | 2003-09-29 | 2005-05-31 | Tenneco Automotive Operating Company Inc. | Extra support area for valve disc |
| AU2005255019B2 (en) * | 2004-06-12 | 2011-05-19 | Oregon Health And Science University | Compositions and methods for diagnosis and treatment of orthopoxviruses |
| US7278987B2 (en) * | 2004-07-09 | 2007-10-09 | Anthony Solazzo | Ergonomic urological catheterization/irrigation tray |
| WO2007044033A2 (fr) | 2004-12-07 | 2007-04-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Récepteur non restreint par le cmh cloné de l'antigène spécifique de tumeur muc1 pour applications thérapeutiques et diagnostiques |
| EP2311531A1 (fr) | 2005-12-01 | 2011-04-20 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Composés de griffithsin antiviraux, compositions et procédés d'utilisation correspondants |
| CN102408470A (zh) | 2005-12-23 | 2012-04-11 | 洛桑大学 | 用作神经递质分泌抑制剂和肌肉松弛诱导物的合成肽 |
| US7868228B2 (en) | 2006-01-31 | 2011-01-11 | Monsanto Technology Llc | Phosphopantetheinyl transferases from bacteria |
| ES2828739T3 (es) | 2006-04-07 | 2021-05-27 | Aerpio Pharmaceuticals Inc | Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos |
| US8846685B2 (en) | 2006-06-27 | 2014-09-30 | Aerpio Therapeutics Inc. | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7622593B2 (en) * | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7589212B2 (en) * | 2006-06-27 | 2009-09-15 | Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| US7795444B2 (en) | 2006-06-27 | 2010-09-14 | Warner Chilcott Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| JO2913B1 (en) | 2008-02-20 | 2015-09-15 | امجين إنك, | Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses |
| WO2009158432A2 (fr) | 2008-06-27 | 2009-12-30 | Amgen Inc. | Inhibition de l’ang-2 pour traiter la sclérose en plaques |
| WO2010011994A2 (fr) | 2008-07-25 | 2010-01-28 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Polypeptides et leurs utilisations |
| CA2737595C (fr) | 2008-10-14 | 2017-09-12 | Monsanto Technology Llc | Utilisation d'acide gras desaturases de hemiselmis spp. |
| US9096555B2 (en) | 2009-01-12 | 2015-08-04 | Aerpio Therapeutics, Inc. | Methods for treating vascular leak syndrome |
| BRPI1006897A2 (pt) | 2009-07-06 | 2015-09-08 | Akebia Therapeutics Inc | compostos, composições e métodos de prevenção da metástase de células cancerosas. |
| US8883832B2 (en) | 2009-07-06 | 2014-11-11 | Aerpio Therapeutics Inc. | Compounds, compositions, and methods for preventing metastasis of cancer cells |
| WO2012009705A1 (fr) | 2010-07-15 | 2012-01-19 | Zyngenia, Inc. | Complexes liant ang-2 et leurs utilisations |
| US20140088019A1 (en) | 2011-02-11 | 2014-03-27 | Zyngenia, Inc. | Monovalent and Multivalent Multispecific Complexes and Uses Thereof |
| DK2714738T3 (en) | 2011-05-24 | 2019-01-28 | Zyngenia Inc | MULTIVALENT AND MONOVALENT MULTISPECIFIC COMPLEXES AND THEIR APPLICATIONS |
| WO2013025479A1 (fr) | 2011-08-16 | 2013-02-21 | Emory University | Agents spécifiques de liaison à jaml, anticorps, et leurs utilisations associées |
| MX363351B (es) | 2011-10-13 | 2019-03-20 | Aerpio Therapeutics Inc | Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular. |
| MX2015013163A (es) | 2013-03-15 | 2016-04-04 | Zyngenia Inc | Complejos multiespecificos multivalente y monovalentes y sus usos. |
| EP2813849A1 (fr) * | 2013-06-10 | 2014-12-17 | Charité-Universitätsmedizin Berlin (Charité) | Signature immunitaire EBV-spécifique comme marqueurs de diagnostique dans le syndrome de fatigue chronique (CFS) |
| US11034736B2 (en) | 2014-01-09 | 2021-06-15 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-viral cnidarins |
| WO2016130628A1 (fr) | 2015-02-10 | 2016-08-18 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Mutants de griffithsine |
| WO2016130899A1 (fr) | 2015-02-13 | 2016-08-18 | The Board Of Trustees Of The University Of Illinois | Inhibition peptidique des maladies ou affections médiées par le ccr3 |
| KR20180034390A (ko) | 2015-06-15 | 2018-04-04 | 모나쉬 유니버시티 | Il-37 변이체 |
| US10703786B2 (en) | 2015-10-30 | 2020-07-07 | The University Of Melbourne | Methods and compositions for improving glucose metabolism |
| SG11201901393VA (en) | 2016-09-02 | 2019-03-28 | Univ Illinois | Kif13b-derived peptide and method of inhibiting angiogenesis |
| CN108490177B (zh) * | 2018-02-08 | 2020-12-29 | 深圳市新产业生物医学工程股份有限公司 | 鼻咽癌抗体检测试剂、其制备方法及鼻咽癌检测试剂盒 |
| WO2021021774A1 (fr) | 2019-07-29 | 2021-02-04 | The Board Of Trustees Of The University Of Illinois | Composition et méthode pour favoriser la cicatrisation des plaies |
| US12497434B2 (en) | 2019-12-20 | 2025-12-16 | Hoffmann-La Roche Inc. | IL-37 fusion proteins and uses thereof |
| CA3199368A1 (fr) | 2020-11-18 | 2022-05-27 | United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Peptides a blocage de tyrosyle |
| AU2023241819A1 (en) | 2022-04-01 | 2024-11-07 | The Board Of Trustees Of The University Of Illinois | Notch1 and notch4 decoys and methods of use |
| CN115684584B (zh) * | 2022-11-01 | 2026-04-21 | 郑州安图生物工程股份有限公司 | Eb病毒磁微粒化学发光检测试剂盒 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE45285T1 (de) * | 1983-11-07 | 1989-08-15 | Wistar Inst | Durch antiidiotype antikoerper induzierte immune antwort zu tumoren und viren. |
| US4699880A (en) * | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
| IE873041L (en) * | 1987-11-11 | 1989-05-11 | Ailbe Brennan | Viral antigens, diagnostic assay therefor and vaccines¹containing them |
| AU6164890A (en) * | 1989-08-10 | 1991-03-11 | Northwestern University | Method of identifying herpesviruses and oligonucleotides for use therein |
| EP0585216A1 (fr) * | 1989-11-24 | 1994-03-09 | The Council Of The Queensland Institue Of Medical Research | Peptides contre la mononucleose infectieuse |
| MX9203409A (es) * | 1989-12-20 | 1992-07-01 | Schering Corp | Proteinas bcrfi como inhibidores de la gama interferona. |
| JPH04310861A (ja) * | 1991-04-09 | 1992-11-02 | Kazuo Yanagi | 抗ebna抗体の測定方法および抗ebna抗体測定キット |
-
1993
- 1993-03-10 DE DE69332197T patent/DE69332197T2/de not_active Expired - Lifetime
- 1993-03-10 AT AT93200691T patent/ATE222291T1/de not_active IP Right Cessation
- 1993-03-10 AT AT02075193T patent/ATE380243T1/de not_active IP Right Cessation
- 1993-03-10 PT PT93200691T patent/PT574048E/pt unknown
- 1993-03-10 EP EP02075193A patent/EP1225226B1/fr not_active Expired - Lifetime
- 1993-03-10 DK DK93200691T patent/DK0574048T3/da active
- 1993-03-10 DE DE69334191T patent/DE69334191T2/de not_active Expired - Lifetime
- 1993-03-10 ES ES93200691T patent/ES2184735T3/es not_active Expired - Lifetime
- 1993-03-10 ES ES02075193T patent/ES2298325T3/es not_active Expired - Lifetime
- 1993-03-10 DK DK02075193T patent/DK1225226T3/da active
- 1993-03-10 EP EP93200691A patent/EP0574048B1/fr not_active Expired - Lifetime
- 1993-03-12 AU AU35152/93A patent/AU666920B2/en not_active Expired
- 1993-03-12 ZA ZA931797A patent/ZA931797B/xx unknown
- 1993-03-12 CA CA002092680A patent/CA2092680C/fr not_active Expired - Lifetime
- 1993-03-12 FI FI931109A patent/FI114802B/fi not_active IP Right Cessation
- 1993-03-12 US US08/031,148 patent/US5424398A/en not_active Expired - Lifetime
- 1993-03-13 KR KR1019930003940A patent/KR100291247B1/ko not_active Expired - Lifetime
- 1993-03-15 JP JP08009993A patent/JP4135996B2/ja not_active Expired - Lifetime
-
2004
- 2004-03-31 JP JP2004102197A patent/JP4106041B2/ja not_active Expired - Lifetime
-
2008
- 2008-03-31 JP JP2008089543A patent/JP4365440B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| JP4106041B2 (ja) | 2008-06-25 |
| PT574048E (pt) | 2002-12-31 |
| ES2184735T3 (es) | 2003-04-16 |
| ES2298325T3 (es) | 2008-05-16 |
| EP1225226B1 (fr) | 2007-12-05 |
| FI931109L (fi) | 1993-09-14 |
| AU3515293A (en) | 1993-09-16 |
| JP4365440B2 (ja) | 2009-11-18 |
| DE69332197D1 (de) | 2002-09-19 |
| JP2008261851A (ja) | 2008-10-30 |
| CA2092680A1 (fr) | 1993-09-14 |
| ATE222291T1 (de) | 2002-08-15 |
| EP0574048A3 (fr) | 1994-03-02 |
| FI931109A0 (fi) | 1993-03-12 |
| EP0574048B1 (fr) | 2002-08-14 |
| KR930019829A (ko) | 1993-10-19 |
| EP0574048A2 (fr) | 1993-12-15 |
| KR100291247B1 (ko) | 2001-06-01 |
| JP4135996B2 (ja) | 2008-08-20 |
| JPH0690787A (ja) | 1994-04-05 |
| CA2092680C (fr) | 2006-08-08 |
| DK1225226T3 (da) | 2008-04-14 |
| AU666920B2 (en) | 1996-02-29 |
| FI114802B (fi) | 2004-12-31 |
| DE69334191D1 (de) | 2008-01-17 |
| JP2004261183A (ja) | 2004-09-24 |
| DE69332197T2 (de) | 2003-04-17 |
| DE69334191T2 (de) | 2008-11-27 |
| DK0574048T3 (da) | 2002-12-16 |
| EP1225226A1 (fr) | 2002-07-24 |
| ATE380243T1 (de) | 2007-12-15 |
| US5424398A (en) | 1995-06-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0574048A3 (fr) | ||
| EP0484787A3 (en) | Hcv-specific peptides, process for obtaining them and their use | |
| TW279178B (fr) | ||
| UA50829C2 (uk) | Очищений поліпептид, що містить антиген вірусу гепатиту с, полінуклеотид, вектор, клітини, система експресії, моноклональне антитіло, препарат поліклональних антитіл, нуклеотидна проба, аналітичні набори, спосіб виявлення нуклеїнових кислот, способи імуноаналізу, вакцина, спосіб одержання антитіл | |
| EP0460076A4 (en) | Genetically engineered immunoglobulins | |
| EP0151079A3 (fr) | Vaccin contre le virus d'Epstein-Barr | |
| DK61595A (da) | Rekombinant DNA-molekyler, værtscelletransformering dermed, værtsceller indeholdende disse samt fremgangsmåde til fremstilling af et polypeptid af IFN-alfa-typen | |
| CA2020668A1 (fr) | Proteines fusionnees ou hybrides comprenant de la lymphokine et un antigene viral | |
| HU9303703D0 (en) | Hepatitis c virus (hcv) polypeptides | |
| AU3192889A (en) | T cell activation markers | |
| GR860914B (en) | Expression of immunologically reactive viral proteins | |
| CA2057052A1 (fr) | Agent viral de l'hepatire non-a, non-b transmis par voie enterique et epitopes caracteristiques | |
| EP0540645A4 (en) | Methods of use of bovine respiratory syncytial virus recombinant dna, proteins vaccines, antibodies, and transformed cells | |
| MY135991A (en) | A vaccine-induced hepatits b viral strain and uses thereof | |
| ZA948016B (en) | A membrane protein polypeptide having pre-B cell crowth-supporting ability and a gene thereof | |
| JO1885B1 (en) | A method for purifying surface serum for viral hepatitis B, consisting of Bryce 2 peptide | |
| DK326289D0 (da) | Fremgangsmaade til fremstilling af et protein ud fra gaersvampe under anvendelse af et inducerbart system, samt vektorer og transformerede stammer til brug ved fremgangsmaaden | |
| EP0503950A3 (en) | Method of purifying recombinant hepatitis b virus surface proteins from recombinant cells | |
| Roeckel et al. | Biochemical characterization of two Epstein-Barr virus early antigen-associated phosphopolypeptides | |
| Middeldorp et al. | Peptides and nucleic acid sequences related to the Epstein Barr virus | |
| RU93043621A (ru) | Способы получения гликопротеинов нсv, способ очистки, аналитический набор, способ выявления нсv, способ элиминации нсv, способ индукции иммунитета, гликопротеины, иммунореагенты | |
| EP0754755A3 (fr) | Protéines, fusionnées recombinantes autologues du virus d'Epstein-Barr, trousse d'essais les contenant ainsi que procédé pour la détection d'anticorps spécifiques du virus d'Epstein-Barr | |
| CA2084521A1 (fr) | Polypeptide de l'antigene du virus de l'hepatite c, sa methode de fabrication et methode de detection de l'anticorps | |
| LTIP1543A (en) | Process for enzymatic decomposition of recombinant proteins by means of iga-protease, fused protein, recombinant dna, cell | |
| WO1988009809A3 (fr) | Systeme cellulaire pour l'expression d'une proteine recombinante sans production de virus |